More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?

International Journal of Bipolar Disorders

Volumn 3, Issue 1, 2015, Pages

  Nolen, Willem A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bipolar disorder; Guideline; Lithium; Long term treatment

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM SALT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFICACY; HUMAN; LONG TERM CARE; MANIA; META ANALYSIS (TOPIC); MOOD DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC);

EID: 84969377144     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-014-0017-6     Document Type: Article

References (11)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1–50.
2. Bech P. The full story of lithium. A tribute to Mogens Schou (1918-2005). Psychother Psychosom. 2006;75(5):265–9.
3. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217–22.
4. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.
5. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–9.
6. National Institute for Health and Care Excellence (NICE). Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: NICE; 2006. www.nice.org.uk/CG38.
7. National Institute for Health and Care Excellence (NICE). The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care, updated edition. London: NICE; 2014. www.nice.org.uk/CG185.
8. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disorders. 2014; Dec 20;2:15.
9. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.
10. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72(11):1452–64.
11. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.